medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-11-18-24medsovet-1534Research ArticleЦЕРЕБРОВАСКУЛЯРНЫЕ ЗАБОЛЕВАНИЯCEREBROVASCULAR DISEASESВТОРИЧНАЯ ПРОФИЛАКТИКА ИШЕМИЧЕСКОГО ИНСУЛЬТА И КОГНИТИВНЫХ НАРУШЕНИЙSECONDARY PREVENTION OF ISCHEMIC STROKE AND COGNITIVE IMPAIRMENTПАРФЕНОВВ. А.PARFYONOVV. A.

д.м.н., профессор

MD, Prof.

ВЕРБИЦКАЯС. В.VERBITSKAYAS. V.Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian Federation2016301220160111824Copyright © ПАРФЕНОВ В.А., ВЕРБИЦКАЯ С.В., 20162016ПАРФЕНОВ В.А., ВЕРБИЦКАЯ С.В.PARFYONOV V.A., VERBITSKAYA S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1534

Обсуждаются вопросы профилактики ишемического инсульта (ИИ) и когнитивных расстройств (КР) у больных, перенесших ИИ или транзиторную ишемическую атаку. Отмечается эффективность в профилактике ИИ и КР нелекарственных методов (отказ от курения и злоупотребления алкоголем, рациональное питание, снижение избыточного веса, регулярная физическая активность), приема лекарственных средств (антитромботические препараты, антигипертензивные средства, статины). Представлены результаты наблюдения в течения 5,5 лет 350 больных, перенесших инсульт, согласно которым применение нелекарственных методов и регулярная лекарственная терапия снижают риск повторного инсульта, но не позволяют остановить нарастание КР. Отмечается широкое использование в нашей стране препарата Диваза у больных с цереброваскулярным заболеванием, приводятся результаты многоцентрового исследования, анонсируется планируемое плацебо-контролируемое исследование Дивазы по вторичной профилактике ИИ и КР.

Prevention of ischemic stroke (IS) and cognitive impairment (CI) in patients after IS or transient ischemic attack is discussed. The efficacy of non-pharmacological methods for the prevention of IS and CI (cessation of smoking and alcohol abuse, balanced diet, losing excess weight, regular physical activity) along with administration of medicines (antithrombotic agents, antihypertensives, statins) is highlighted. The results of a 5.5-year follow-up of 350 patients after stroke are described which demonstrate that non-pharmacological methods and regular drug therapy reduce the risk of recurrent stroke, though they are not effective in preventing the growing CI. The article tells about the widespread use of Divaza in this country in patients with cerebrovascular disease and the results of a multicenter study are demonstrated; a placebo-controlled Divaza study for secondary prevention of IS and CD is planned.

вторичная профилактика ишемического инсультанелекарственные средства профилактики инсультаантитромботические средстваантигипертензивные средствапостинсультные когнитивные нарушенияДивазаsecondary prevention of ischemic strokenon-pharmacological methods for stroke preventionantithrombotic agentsantihypertensivespost stroke cognitive impairmentDivazaReferencesSacco RL, Adams R, Albers G et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, 2006, 37: 577-617.Sacco RL, Adams R, Albers G et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, 2006, 37: 577-617.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis, 2008, 25: 457-507.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis, 2008, 25: 457-507.Furie KL, Kasner SE, Adams RJ et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2011, 42: 227-276.Furie KL, Kasner SE, Adams RJ et al. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2011, 42: 227-276.Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O’Brien J, Ames D, Gustafson L et al. Martin Dunitz. 2004.Cerebrovascular disease, cognitive impairment and dementia. Second edition of Cerebrovascular disease and dementia. Edited by O’Brien J, Ames D, Gustafson L et al. Martin Dunitz. 2004.Gorelick PB, Scuteri A, Black SE et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2011, 42: 2672-2713.Gorelick PB, Scuteri A, Black SE et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2011, 42: 2672-2713.Eskes GA, Lanctôt KL, Herrmann N et al. Canadi an Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015. Int J Stroke, 2015 Jun 29. doi: 10.1111/ijs.12557Eskes GA, Lanctôt KL, Herrmann N et al. Canadi an Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015. Int J Stroke, 2015 Jun 29. doi: 10.1111/ijs.12557Larrieu S, Letenneur L, Helmer C et al. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging, 2004, 8: 150-154.Larrieu S, Letenneur L, Helmer C et al. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging, 2004, 8: 150-154.Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychological Science, 2003, 14: 125-130.Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychological Science, 2003, 14: 125-130.Scarmeas N, Stern Y, Mayeux R et al. Mediterranean diet and mild cognitive impairment. Arch Neurol, 2009, 66: 216-225.Scarmeas N, Stern Y, Mayeux R et al. Mediterranean diet and mild cognitive impairment. Arch Neurol, 2009, 66: 216-225.Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. Curr Psychiatry Rep, 2010, 12: 20-27.Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. Curr Psychiatry Rep, 2010, 12: 20-27.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324: 71-86.Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324: 71-86.Kernan WN, Ovbiagele B, Black HR. et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2014, 45: 2160-2236.Kernan WN, Ovbiagele B, Black HR. et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2014, 45: 2160-2236.Connolly S, Ezekowitz MD, Ysuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139-1151.Connolly S, Ezekowitz MD, Ysuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139-1151.Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2011, 365: 981-992.Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2011, 365: 981-992.Patel МR, Mahaffey KW, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular trial Fibrillation. N Engl J Med, 2011, 365: 883-891.Patel МR, Mahaffey KW, Garg J et al. Rivaroxaban versus Warfarin in Nonvalvular trial Fibrillation. N Engl J Med, 2011, 365: 883-891.Rashid P, Leonardi-Bee J, Bath PP. Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events. Stroke, 2003, 34: 2741-2748.Rashid P, Leonardi-Bee J, Bath PP. Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events. Stroke, 2003, 34: 2741-2748.Patterson C, Feightner JW, Garcia A et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Canadian Medical Association Journal, 2008, 178: 548-556.Patterson C, Feightner JW, Garcia A et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Canadian Medical Association Journal, 2008, 178: 548-556.Rothwell PM, Howard SC, Spence JD for the Carotide Endarterectomy Trialist`s Collaboration. Relationship between Blood Pressure and Stroke Risk in Patients With Symptomatic Carotid Occlusive Disease. Stroke, 2003, 34: 2583-2592.Rothwell PM, Howard SC, Spence JD for the Carotide Endarterectomy Trialist`s Collaboration. Relationship between Blood Pressure and Stroke Risk in Patients With Symptomatic Carotid Occlusive Disease. Stroke, 2003, 34: 2583-2592.Вербицкая С.В., Парфенов В.А. Вторичная профилактика инсульта в амбулаторных условиях. Неврологический журнал, 2011, 1: 17-21.Вербицкая С.В., Парфенов В.А. Вторичная профилактика инсульта в амбулаторных условиях. Неврологический журнал, 2011, 1: 17-21.Schaapsmeerders P, Maaijwee NAM, van Dijk EJ et al. Long-Term Cognitive Impairment After First-Ever Ischemic Stroke in Young Adults. Stroke, 2013, 44: 1621-1628.Schaapsmeerders P, Maaijwee NAM, van Dijk EJ et al. Long-Term Cognitive Impairment After First-Ever Ischemic Stroke in Young Adults. Stroke, 2013, 44: 1621-1628.Sachdev PS, Lipnicki DM, Crawford JD et al. Progression of cognitive impairment in stroke/ TIA patients over 3 years. J Neurol Neurosurg Psychiatry, 2014, 85: 1324-1330.Sachdev PS, Lipnicki DM, Crawford JD et al. Progression of cognitive impairment in stroke/ TIA patients over 3 years. J Neurol Neurosurg Psychiatry, 2014, 85: 1324-1330.Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012. 288 с.Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012. 288 с.Эпштейн О.И. Сверхмалые дозы (история одного исследования). М.: Издательство РАМН, 2008. 336 с.Эпштейн О.И. Сверхмалые дозы (история одного исследования). М.: Издательство РАМН, 2008. 336 с.Эпштейн О.И., Дыгай А.М., Шерстобоев Е.Ю. и др. Экспериментальное исследование фармакологических эффектов сверхмалых доз антител к эндогенным регуляторам функций. Бюл. экспер. биол. и медицины, 2008, Приложение 2: 82-88.Эпштейн О.И., Дыгай А.М., Шерстобоев Е.Ю. и др. Экспериментальное исследование фармакологических эффектов сверхмалых доз антител к эндогенным регуляторам функций. Бюл. экспер. биол. и медицины, 2008, Приложение 2: 82-88.Камчатнов П.Р., Воробьева О.В., Рачин А.П. Коррекция эмоциональных и когнитивных нарушений у пациентов с хронической ишемией головного мозга. Журнал неврологии и психиатрии, 2014, 4: 52-57.Камчатнов П.Р., Воробьева О.В., Рачин А.П. Коррекция эмоциональных и когнитивных нарушений у пациентов с хронической ишемией головного мозга. Журнал неврологии и психиатрии, 2014, 4: 52-57.

The authors declare that there are no conflicts of interest present.